company background image
A065650 logo

Hyper KOSDAQ:A065650 Stock Report

Last Price

₩1.33k

Market Cap

₩128.7b

7D

12.0%

1Y

30.0%

Updated

28 Nov, 2024

Data

Company Financials

Hyper Corporation Inc.

KOSDAQ:A065650 Stock Report

Market Cap: ₩128.7b

A065650 Stock Overview

A clinical stage biopharmaceutical company, focuses on the development of Alzheimer's disease (AD) and neuropathic pain treatments, and AD diagnostics. More details

A065650 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Hyper Corporation Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Hyper
Historical stock prices
Current Share Price₩1,326.00
52 Week High₩1,697.00
52 Week Low₩920.00
Beta0
11 Month Change9.32%
3 Month Change2.08%
1 Year Change30.00%
33 Year Change-43.69%
5 Year Change-72.49%
Change since IPO-55.80%

Recent News & Updates

Recent updates

Should Medifron DBT (KOSDAQ:065650) Be Disappointed With Their 48% Profit?

Mar 15
Should Medifron DBT (KOSDAQ:065650) Be Disappointed With Their 48% Profit?

Despite Lacking Profits Medifron DBT (KOSDAQ:065650) Seems To Be On Top Of Its Debt

Nov 29
Despite Lacking Profits Medifron DBT (KOSDAQ:065650) Seems To Be On Top Of Its Debt

Shareholder Returns

A065650KR ElectronicKR Market
7D12.0%1.9%0.9%
1Y30.0%-29.5%-3.4%

Return vs Industry: A065650 exceeded the KR Electronic industry which returned -29.5% over the past year.

Return vs Market: A065650 exceeded the KR Market which returned -3.4% over the past year.

Price Volatility

Is A065650's price volatile compared to industry and market?
A065650 volatility
A065650 Average Weekly Movement4.6%
Electronic Industry Average Movement5.8%
Market Average Movement5.7%
10% most volatile stocks in KR Market11.6%
10% least volatile stocks in KR Market2.7%

Stable Share Price: A065650 has not had significant price volatility in the past 3 months compared to the KR market.

Volatility Over Time: A065650's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1997n/aHyun-Sang Mukwww.hyper-corp.com

Hyper Corporation Inc., a clinical stage biopharmaceutical company, focuses on the development of Alzheimer's disease (AD) and neuropathic pain treatments, and AD diagnostics. Its products under development include TRPV1 Antagonist and TRPV1 Agonist for neuropathic pain; and anti-oligomerization of beta-amyloid, receptor for advanced glycation endproduct modulator, and early diagnosis kits for AD. The company wholesales and retails electronic devices, small home appliances, TVs, routers, and PC peripherals, such as gaming monitors, mouse, and wheels; keyboards; headsets; webcams; and sound bars, as well as provides online contents.

Hyper Corporation Inc. Fundamentals Summary

How do Hyper's earnings and revenue compare to its market cap?
A065650 fundamental statistics
Market cap₩128.66b
Earnings (TTM)-₩3.52b
Revenue (TTM)₩31.41b

0.0x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A065650 income statement (TTM)
Revenue₩31.41b
Cost of Revenue₩27.16b
Gross Profit₩4.25b
Other Expenses₩7.78b
Earnings-₩3.52b

Last Reported Earnings

Dec 31, 2020

Next Earnings Date

n/a

Earnings per share (EPS)0
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did A065650 perform over the long term?

See historical performance and comparison